Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (Review)

Zhang,Xianghong; Liu,Tang; Li,Zhihong; Zhang,Xiangsheng

doi:10.3892/ol.2014.2332

Progress of photodynamic therapy applications in the treatment of musculoskeletal sarcoma (Review)

Authors:
- Xianghong Zhang
- Tang Liu
- Zhihong Li
- Xiangsheng Zhang
View Affiliations

Affiliations: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: July 9, 2014 https://doi.org/10.3892/ol.2014.2332
Pages: 1403-1408

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Photodynamic therapy (PDT) has clinical approval for use as a minimally invasive therapeutic procedure that is able to exert selective cytotoxic activity toward pathological cells, particularly malignant cells. Following a number of recent technological improvements, PDT has been widely applied to the diagnosis and treatment of malignancies, including lung, esophageal, gastrointestinal, bladder, prostate, head and neck, oral and skin cancer. Studies have shown that osteosarcoma is a malignant tumor afflicting young adults worldwide, and recently, the incidence of bone and soft‑tissue malignant tumors has been shown to be increasing, so the use of PDT has become an area of focus for the diagnosis and treatment of musculoskeletal sarcoma.

View Figures

View References

1	Sharma SK, Mroz P, Dai T, Huang YY, St Denis TG and Hambin MR: Photodynamic therapy for cancer and for infections: What is the difference? Isr J Chem. 52:691–705. 2012.
2	Brown SB, Brown EA and Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5:497–508. 2004.
3	Allison RR, Mota HC and Sibata CH: Clinical PD/PDT in North America: an historical review. Photodiagnosis Photodyn Ther. 1:263–277. 2004.
4	Dougherty TJ: Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol. 2:83–116. 1984.
5	Hayata Y, Kato H, Konaka C, et al: Photoradiation therapy with hematoporphyrin derivative in early and stage 1 lung cancer. Chest. 86:169–177. 1984.
6	McCaughan JS Jr, Ellison EC, Guy JT, et al: Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg. 62:1005–1010. 1996.
7	Cheung J, Todd M, Turnbull R, et al: Longer term assessment of photodynamic therapy for Intimal Hyperplasia: a pilot Study. J Photochem Photobiol B. 73:141–147. 2004.
8	Cheung G, Sahai A, Billia M, Dasgupta P and Khan MS: Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 11:132013.
9	Bhowmick R and Girotti AW: Pro-survival and pro-growth effects of stress-induced nitric oxide in a prostate cancer photodynamic therapy model. Cancer Lett. 343:115–122. 2014.
10	Hwang H, Biswas R, Chung PS and Ahn JC: Modulation of EGFR and ROS induced cytochrome c release by combination of photodynamic therapy and carboplatin in human cultured head and neck cancer cells and tumor xenograft in nude mice. J Photochem Photobiol B. 128:70–77. 2013.
11	Rigual N, Shafirstein G, Cooper MT, et al: Photodynamic therapy with 3-(1′-Hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin Cancer Res. 19:6605–6613. 2013.
12	Shi L, Wang X, Zhao F, et al: In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles. Int J Nanomedicine. 8:2669–2676. 2013.
13	Allison RR and Moghissi K: Photodynamic therapy (PDT): PDT mechanisms. Clin Endosc. 46:24–29. 2013.
14	Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H and Uchida A: Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. Anticancer Res. 26:187–193. 2006.
15	Sibata CH, Colussi VC, Oleinick NL and Kinsella TJ: Photodynamic therapy in oncology. Expert Opin Pharmacother. 2:917–927. 2001.
16	Oleinick NL, Morris RL and Belichenko I: The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 1:1–21. 2002.
17	Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2:277–288. 2002.
18	Oleinick NL and Evans HH: The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 150(5 Suppl): S146–S156. 1998.
19	Ding X, Xu Q, Liu F, et al: Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation. Cancer Lett. 216:43–54. 2004.
20	Henderson BW and Donovan JM: Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res. 49:6896–6900. 1989.
21	Castano AP, Demidova TN and Hamblin MR: Mechanisms in photodynamic therapy: part three - photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther. 2:91–106. 2005.
22	Castano AP, Demidova TN and Hamblin MR: Mechanisms in photodynamic therapy: part two - cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2:1–23. 2005.
23	Henderson BW and Dougherty TJ: Review article: How does photodynamic therapy work? Photochem Photobiol. 55:145–157. 1992.
24	Kurohane K, Tominaga A, Sato K, North JR, Namba Y and Oku N: Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 167:49–56. 2001.
25	Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ and Sibata CH: Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther. 1:27–42. 2004.
26	De Rosa FS and Bentley MV: Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm Res. 17:1447–1455. 2000.
27	Allison RR and Sibata CH: Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 7:61–75. 2010.
28	Vrouenraets MB, Visser GW, Snow GB and van Dongen GA: Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 23:505–522. 2003.
29	Kennedy JC and Pottier RH: Endogenous protoporphyin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 14:275–292. 1992.
30	Burch S, Boqaards A, Siewerdsen J, et al: Photodynamic therapy for the treatment of metastatic lesions in bone: studies in rat and porcine models. J Biomed Opt. 10:0340112005.
31	Huang Z: A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 4:283–293. 2005.
32	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, et al: Photodynamic therapy of cancer: an update. CA Cancer J Clin. 61:250–281. 2011.
33	Castano AP, Demidova TN and Hamblin MR: Mechanisms in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther. 1:279–293. 2004.
34	Ochsner M: Light scattering of human skin: a comparison between zinc (II)-phthalocyanine and photofrin II. J Photobiol B. 32:3–9. 1996.
35	Robertson CA, Evans DH and Abrahamse H: Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B. 96:1–8. 2009.
36	Satonaka H, Kusuzaki K, Matsubara T, Shintani K, Wakabayashi T, Nakamura T, et al: Flash wave light strongly enhanced the cytocidal effect of photodynamic therapy with acridine orange on a mouse osteosarcoma cell line. Anticancer Res. 27:3339–3344. 2007.
37	Alexiades-Armenakas M: Laser-mediated photodynamic therapy. Clin Dermatol. 24:16–25. 2006.
38	Hamblin MR, Rajadhyaksha M, Momma T, Soukos NS and Hasan T: In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour. Br J Cancer. 81:261–268. 1999.
39	Kurohane K, Tominaga A, Sato K, North JR, Namba Y and Oku N: Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 167:49–56. 2001.
40	Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT and Bellnier DA: Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res. 11:4241–4250. 2005.
41	Rasalkar DD, Chu WC, Lee V, Paunipagar BK, Cheng FW and Li CK: Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol. 41:227–236. 2011.
42	Tian Z, Quan X, Xu C, Dan L, Guo H and Leung W: Hematoporphyrin monomethyl ether enhances the killing action of ultrasound on osteosarcoma in vivo. J Ultrasound Med. 28:1695–1702. 2009.
43	Nomura L, Yanase S, Matsumura Y, Nagai K and Tagawa T: Efficacy of combined photodynamic and hyperthermic therapy with a new light source in an in vivo osteosarcoma tumor model. J Clin Laser Med Surg. 22:3–8. 2004.
44	Hashiguchi S, Kusuzaki K, Murata H, et al: Acridine orange excited by low-dose radiation has a strong cytocidal effect on mouse osteosarcoma. Oncology. 62:85–93. 2002.
45	Messmann H, Knuchel R, Baumler W, et al: Endoscopic fluorescence detection of dysplasia in patients with Barrett’s esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. Gastrointest Endosc. 49:97–101. 1999.
46	Stübel H: The fluorescence of animal tissues in ultraviolet light. Pflüger’s Archiv für die gesamte Physiologie des Menschen und der Tiere. 142:1–14. 1911.(In German).
47	Kusuzaki K, Suginoshita T, Minami G, et al: Fluorovisualization effect of acridine orange on mouse osteosarcoma. Anticancer Res. 20:3019–3024. 2000.
48	Kusuzaki K, Aomori K, Suginoshita T, et al: Total tumor cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas following photodynamic therapy with acridine orange. Oncology. 59:174–180. 2000.
49	Kusuzaki K, Murata H, Matsubara T, Satonaka H, Wakabayashi T, Matsumine A and Uchida A: Review. Acridine orange could be an innovative anticancer agent under photon energy. In vivo. 21:205–214. 2007.
50	Satonaka H, Kusuzaki K, Matsubara T, Shintani K, Wakabayashi T, Matsumine A and Uchida A: Extracorporeal photodynamic image detection of mouse osteosarcoma in soft tissues utilizing fluorovisualization effect of acridine orange. Oncology. 70:465–473. 2006.
51	Kusuzaki K, Murata H, Matsubara T, et al: Clinical trial of photodynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. Anticancer Res. 25:1225–1235. 2005.
52	Matsubara T, Kusuzaki K, Matsumine A, Satonaka H, Shintani K, Nakamura T and Uchida A: Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma. In Vivo. 22:297–303. 2008.
53	Hickman JA: Apoptosis and tumourigenesis. Curr Opin Genet Dev. 12:67–72. 2002.
54	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000.
55	Springfield DS: Introduction to limb-salvage surgery for sarcomas. Orthop Clin North Am. 22:1–5. 1991.
56	Kusuzaki K, Aomori K, Suginoshita T, et al: Total tumor cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas following photodynamic therapy with acridine orange. Oncology. 59:174–180. 2000.
57	Kusuzaki K, Murata H, Takeshita H, et al: Intracellular binding sites of acridine orange in living osteosarcoma cells. Anticancer Res. 20:971–975. 2000.
58	Wright EH, Gwilym S, Gibbons CL, Critchley P and Giele HP: Functional and oncological outcomes after limb-salvage surgery for primary sarcomas of the upper limb. J Plast Reconstr Aesthet Surg. 61:382–387. 2008.
59	Ueda H, Murata H, Takeshita H, Minami G, Hashiguchi S and Kubo T: Unfiltered xenon light is useful for photodynamic therapy with acridine orange. Anticancer Res. 25:3979–3983. 2005.
60	Kusuzaki K, Minami G, Takeshita H, et al: Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J Cancer Res. 91:439–445. 2000.
61	Wu PK, Chen WM, Chen CF, Lee OK, Haung CK and Chen TH: Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol. 39:514–522. 2009.
62	Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S and Yoshikawa H: Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 76:418–422. 1998.
63	Satonaka H, Kusuzaki K, Akeda K, et al: Acridine orange inhibits pulmonary metastasis of mouse osteosarcoma. Anticancer Res. 31:4163–4168. 2011.
64	Kusuzaki K, Murata H, Matsubara T, et al: Clinical outcome of a novel photodynamic therapy technique using acridine orange for synovial sarcomas. Photochem Photobiol. 81:705–709. 2005.
65	Yoshida K, Kusuzaki K, Matsubara T, et al: Periosteal Ewing’s sarcoma treated by photodynamic therapy with acridine orange. Oncol Rep. 13:279–282. 2005.
66	Matsubara T, Matsumine A, Kusuzaki K, et al: A minimally invasive surgery for bone metastases using the combination of photodynamic therapy and hyperthermia treatment. Inter J Clin Med. 4:357–363. 2013.